Antisense Oligonucleotides Have Been in Clinical Trials for Cancer for Some Time Now - Drug Delivery in Cancer - Technologies, Markets and Companies Report 2007
Posted on: Friday, 2 February 2007, 12:00 CST
Research and Markets (http://www.researchandmarkets.com/reports/c1346) has announced the addition of 'Drug Delivery in Cancer - Technologies, Markets and Companies Report' to their offering.
Drug delivery remains a challenge in management of cancer. Approximately 12.5 million new cases of cancer are being diagnosed worldwide each year and considerable research is in progress for drug discovery for cancer. Cancer drug delivery is no longer simply wrapping up cancer drugs in new formulations for different routes of delivery. The focus is on targeted cancer therapy. The newer approaches to cancer treatment not only supplement the conventional chemotherapy and radiotherapy but also prevent damage to normal tissues and prevent drug resistance.
Innovative cancer therapies are based on current concepts of molecular biology of cancer. These include antiangiogenic agents, immunotherapy, bacterial agents, viral oncolysis, targeting of cyclic-dependent kinases and tyrosine kinase receptors, antisense approaches, gene therapy and combination of various methods. Important methods of immunotherapy in cancer involve use of cytokines, monoclonal antibodies, cancer vaccines and immunogene therapy.
Several innovative methods of drug delivery are used in cancer. These include use of microparticles as carriers of anticancer agents. These may be injected into the arterial circulation and guided to the tumor by magnetic field for targeted drug delivery. Polyethylene glycol (PEG) technology has been used to overcome some of the barriers to anticancer drug delivery. Encapsulating anticancer drugs in liposomes enables targeted drug delivery to tumor tissues and prevents damage to the normal surrounding tissues. Monoclonal antibodies can be used for the delivery of anticancer payloads such as radionucleotides, toxins and chemotherapeutic agents to the tumors.
Antisense oligonucleotides have been in clinical trials for cancer for some time now. RNAi has also been applied in oncology. Small interfering RNAs (siRNAs) can be targeted to tumors and one example is suppression of H-ras gene expression indicating the potential for application in therapy of ovarian cancer. Cancer gene therapy is a sophisticated form of drug delivery for cancer. Various technologies and companies developing them are described. Nucleic acid-based cancer vaccines are also described.
Drug delivery strategies vary according to the type and location of cancer. Role of drug delivery in the management of cancers of the brain, the bladder, the breast, the ovaries and the prostate are used as examples to illustrate different approaches both experimental and clinical. Biodegradable implants of carmustine are already used in the treatment of malignant brain tumors.
The market value of drug delivery technologies and the anticancer drugs are difficult to separate. Cancer market estimates from 2006-2015 are given according to organs involved and the types of cancer as well as according to technologies. Distribution of the into major regions is also described.
Profiles of 175 companies involved in developing innovative cancer therapies and methods of delivery are presented along with their 169 collaborations. The bibliography contains over 400 publications that are cited in the report. The report is supplemented with 50 tables and 7 figures
Content Outline:
0. Executive Summary
1. Introduction to cancer therapy
2. Innovative treatments for cancer
3. Drug delivery systems for cancer
4. Antisense, RNAi and Gene Therapy for Cancer
5. Delivery strategies according to cancer type and location
6. Cancer drug delivery markets
7. References
List of Tables
List of Figures
For more information visit (http://www.researchandmarkets.com/reports/c1346)
Source: Jain PharmaBiotech
Source: Business Wire
Related Articles
- Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non-Small-Cell Lung Cancer Drug Market to Nearly Triple to Almost $10 Billion in 2018
- Iressa beneficial as gene-targeting drug
- Drug Eluting Nanostructured Coatings Enable Targeted Drug Therapy for Patients With Orthopedic Implants, According to New Research
- Ovarian Cancer: Platinum-Based Therapy Still the Gold Standard
- Study Examines Side Effects of Breast Cancer Prevention Drugs
- Rexahn and University of Maryland Nanomedicine Center Join to Develop Cancer and CNS Therapies
- Cancer Wonder Drug is Hailed
- Cancer 'Wonder Drug' Brings New Hope for Women Treatment for Breast Disease Approved for Scots Patients
- Safe and Effective Drug Therapy in Older Adults
- When Epilepsy Drug Therapy Fails
 |
 |
User Comments (0)
RSS Feeds